emodin has been researched along with Diabetic Glomerulosclerosis in 9 studies
Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.
emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with emodin significantly turns down the accelerated cell cycle and proliferation of MCs cultured in high glucose (HG) via inhibiting cFLIP." | 5.40 | Emodin suppresses hyperglycemia-induced proliferation and fibronectin expression in mesangial cells via inhibiting cFLIP. ( Cao, S; Gao, J; Guo, C; Su, Z; Wang, F; Wang, W, 2014) |
| "Treatment of Emodin in DKD models could significantly attenuated these changes and reduced renal injury." | 1.91 | Emodin attenuates diabetic kidney disease by inhibiting ferroptosis via upregulating Nrf2 expression. ( Cao, M; Cui, M; Ji, J; Tao, P; Wang, Q; Xu, Y, 2023) |
| "Treatment with emodin significantly turns down the accelerated cell cycle and proliferation of MCs cultured in high glucose (HG) via inhibiting cFLIP." | 1.40 | Emodin suppresses hyperglycemia-induced proliferation and fibronectin expression in mesangial cells via inhibiting cFLIP. ( Cao, S; Gao, J; Guo, C; Su, Z; Wang, F; Wang, W, 2014) |
| "Emodin was efficient to ameliorate renal dysfunction in diabetic nephropathy rats probably by its inhibition of the activation of p38 MAPK pathway and downregulation of the expression of fibronectin." | 1.33 | Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats. ( Chen, F; Guo, F; Huang, H; Huang, W; Liu, P; Liu, W; Qin, J; Tang, F; Wang, J; Yang, B, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, Y | 1 |
| Yan, YM | 1 |
| Wei, W | 1 |
| Luo, J | 1 |
| Zhang, LS | 1 |
| Zhou, XJ | 1 |
| Wang, PC | 1 |
| Yang, YX | 1 |
| Cheng, YX | 1 |
| Fu, S | 1 |
| Zhou, Y | 1 |
| Hu, C | 1 |
| Xu, Z | 1 |
| Hou, J | 1 |
| Ji, J | 1 |
| Tao, P | 1 |
| Wang, Q | 1 |
| Cui, M | 1 |
| Cao, M | 1 |
| Xu, Y | 1 |
| Tian, N | 1 |
| Gao, Y | 1 |
| Wang, X | 1 |
| Wu, X | 1 |
| Zou, D | 1 |
| Zhu, Z | 1 |
| Han, Z | 1 |
| Wang, T | 1 |
| Shi, Y | 1 |
| Gao, J | 1 |
| Wang, F | 1 |
| Wang, W | 1 |
| Su, Z | 1 |
| Guo, C | 1 |
| Cao, S | 1 |
| Sohn, E | 1 |
| Kim, J | 1 |
| Kim, CS | 1 |
| Jo, K | 1 |
| Kim, JS | 1 |
| Xu, S | 1 |
| Lv, Y | 1 |
| Zhao, J | 1 |
| Wang, J | 2 |
| Zhao, X | 1 |
| Wang, S | 1 |
| Gu, L | 1 |
| Wan, Y | 1 |
| Wan, M | 1 |
| Huang, H | 1 |
| Liu, P | 1 |
| Tang, F | 1 |
| Qin, J | 1 |
| Huang, W | 1 |
| Chen, F | 1 |
| Guo, F | 1 |
| Liu, W | 1 |
| Yang, B | 1 |
1 review available for emodin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
[Advances in the study on molecular mechanism of diabetic nephropathy treated with Rheum officinale].
Topics: Animals; Anthraquinones; Cytokines; Diabetic Nephropathies; Drugs, Chinese Herbal; Emodin; Humans; I | 2003 |
8 other studies available for emodin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Anthraquinone derivatives from Rumex plants and endophytic Aspergillus fumigatus and their effects on diabetic nephropathy.
Topics: Anthraquinones; Aspergillus fumigatus; Cell Survival; Diabetic Nephropathies; Dose-Response Relation | 2013 |
Network pharmacology and molecular docking technology-based predictive study of the active ingredients and potential targets of rhubarb for the treatment of diabetic nephropathy.
Topics: Diabetes Mellitus; Diabetic Nephropathies; Emodin; Humans; Molecular Docking Simulation; Network Pha | 2022 |
Emodin attenuates diabetic kidney disease by inhibiting ferroptosis via upregulating Nrf2 expression.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Emodin; Ferroptosis; | 2023 |
Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy.
Topics: Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Diabetic Nephropathies; Dose-Response Relat | 2018 |
Emodin suppresses hyperglycemia-induced proliferation and fibronectin expression in mesangial cells via inhibiting cFLIP.
Topics: Animals; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Cycle Checkpoints; Cell P | 2014 |
Extract of Rhizoma Polygonum cuspidatum reduces early renal podocyte injury in streptozotocin‑induced diabetic rats and its active compound emodin inhibits methylglyoxal‑mediated glycation of proteins.
Topics: Animals; Apoptosis; Caspase 3; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Emodin; Fall | 2015 |
Inhibitory effects of Shenkang injection and its main component emodin on the proliferation of high glucose‑induced renal mesangial cells through cell cycle regulation and induction of apoptosis.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line; Cell Proliferation; Diabetic Nephropathies; Drugs, Chines | 2016 |
Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats.
Topics: Actins; Animals; Blood Glucose; Blotting, Western; Body Weight; Cyclic AMP Response Element-Binding | 2006 |